Halozyme Therapeutics (NASDAQ:HALO) Director Mahesh Krishnan Sells 7,304 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $78.27 on Wednesday. The company’s fifty day moving average is $68.81 and its 200-day moving average is $69.12. Halozyme Therapeutics, Inc. has a 12 month low of $51.78 and a 12 month high of $82.22. The firm has a market cap of $9.28 billion, a price-to-earnings ratio of 28.15, a price-to-earnings-growth ratio of 0.32 and a beta of 0.88. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. Halozyme Therapeutics’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Larson Financial Group LLC increased its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the period. Measured Wealth Private Client Group LLC grew its stake in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Clearstead Advisors LLC grew its stake in shares of Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 265 shares during the last quarter. Harbour Investments Inc. increased its position in Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 372 shares during the period. Finally, Wexford Capital LP bought a new position in Halozyme Therapeutics during the third quarter worth $70,000. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Morgan Stanley lowered their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, UBS Group restated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.